ebola
viru
ebov
marburg
viru
marv
member
filovirida
famili
envelop
negativestrand
rna
virus
caus
agent
highli
lethal
diseas
approv
vaccin
treatment
current
avail
due
virul
biothreat
potenti
filovirus
classifi
categori
pathogen
ongo
ebov
epidem
west
africa
longest
widespread
filoviru
outbreak
record
like
filovirus
ebov
display
singl
virusencod
protein
viral
glycoprotein
gp
surfac
virion
ebov
gp
class
membran
fusion
glycoprotein
howev
ebov
gp
differ
canon
class
fusion
protein
human
immunodefici
viru
influenza
viru
architectur
fusion
loop
close
resembl
class
ii
iii
glycoprotein
ebov
gp
synthes
precursor
polypeptid
assembl
trimer
endoplasm
reticulum
subunit
posttransl
cleav
golgi
endoproteas
furin
yield
disulfidelink
kda
kda
subunit
final
gp
assembl
kda
trimer
heterodim
display
surfac
matur
ebov
virion
contain
receptorbind
site
regul
trigger
membran
fusion
machineri
subunit
structur
divid
three
subdomain
mucin
domain
glycan
cap
core
outer
mucin
domain
residu
predict
loos
structur
heavili
glycosyl
incorpor
five
nlink
glycan
predict
olink
glycan
interior
mucinlik
domain
glycan
cap
residu
sit
atop
core
glycan
cap
order
mucinlik
domain
contain
four
nlink
glycosyl
site
neither
mucin
glycan
cap
domain
essenti
viral
entri
inde
remov
domain
enhanc
infect
virus
pseudotyp
ebov
gp
therefor
current
hypothes
primari
function
mucin
domain
glycan
cap
shield
core
immun
surveil
ebov
virion
intern
cell
via
macropinocytosislik
mechan
undergo
traffick
late
endosom
host
endosom
cystein
proteas
includ
cathepsin
l
catl
b
catb
cleav
remov
mucin
glycan
cap
domain
cleavag
gener
fusioncompet
gp
trimer
gpcl
compris
core
domain
cleavag
gpcl
prerequisit
viral
recognit
host
endosom
receptor
niemannpick
strongli
suggest
receptorbind
site
core
structur
unmask
cleavag
late
endosom
thu
gpcl
repres
structur
ebov
gp
conform
compet
receptor
bind
order
observ
possibl
structur
chang
gpcl
illustr
definit
surfac
residu
unveil
upon
endosom
proteolysi
determin
crystal
structur
ebov
gpcl
trimer
resolut
complex
neutral
human
antibodi
fab
found
main
featur
expos
upon
prime
ebov
gp
wavelik
morpholog
top
gpcl
polarbas
crest
rise
larg
recess
hydrophob
trough
previous
occupi
glycan
cap
prior
prime
host
cathepsin
extens
structuredirect
mutagenesi
ebov
gpcl
reveal
basic
charact
polar
crest
crucial
ebovreceptor
interact
like
confer
initi
electrostat
attract
gpcl
second
lumin
domain
domain
c
also
find
trough
make
specif
hydrophob
contact
essenti
highaffin
domain
c
bind
final
demonstr
hostprogram
unmask
site
ebov
gp
creat
broadli
conserv
target
neutral
monoclon
antibodi
mab
recent
isol
human
survivor
marv
infect
result
thu
suggest
novel
approach
develop
engin
mab
broadspectrum
activ
filovirus
purifi
ebov
ectodomain
express
without
mucinlik
domain
hereinaft
refer
gp
treat
thermolysin
mimic
host
endosom
proteas
process
ebov
gp
order
gener
ebov
gpcl
trimer
crystal
ebov
gpcl
crystal
space
group
h
four
gp
monom
four
fab
asymmetr
unit
asu
asu
contain
one
full
gp
trimer
one
remain
gp
monom
form
biolog
relev
trimer
two
symmetryrel
protom
crystallograph
axi
overal
chang
tertiari
structur
upon
cleavag
gp
minim
reflect
root
mean
squar
deviat
rmsd
compar
structur
uncleav
ebov
gp
fig
find
corrobor
previou
model
ebov
gpcl
suggest
limit
chang
gpcl
structur
upon
thermolysin
digest
structur
ebov
gpcl
compact
ebov
gp
exhibit
stabl
crystal
pack
less
disord
improv
resolut
xray
diffract
previous
determin
uncleav
gp
new
region
ebov
gp
visual
ebov
gpcl
structur
includ
ctermin
residu
disulfid
link
disulfid
bond
ebov
descend
base
gp
trimer
structur
form
tightli
order
loop
structur
stabil
disulfid
bond
disulfid
link
turn
peptid
chain
back
toward
bodi
gp
anchor
disulfid
bond
prior
turn
downward
toward
transmembran
domain
viral
membran
fig
strike
structur
featur
gpcl
full
exposur
charg
hydrophil
crest
larg
hydrophob
trough
structur
immedi
proxim
fusion
loop
trough
becom
expos
upon
proteolyt
excis
glycan
cap
ebov
gp
wide
long
deep
fig
residu
form
expos
hydrophob
face
insid
trough
residu
line
bottom
trough
previou
work
util
scan
mutagenesi
ebov
gp
identifi
multipl
residu
import
viral
infect
studi
carri
prior
avail
crystal
structur
ebov
gp
gpcl
work
prior
identif
endosom
receptor
map
residu
onto
crystal
structur
ebov
gpcl
determin
whether
mutat
ebov
gp
reduc
infect
specif
correl
defect
bind
previou
work
identifi
three
lysin
posit
hydrophob
residu
mutat
alanin
diminish
infect
deficit
infect
correl
reduct
bind
determin
coimmunoprecipit
crystal
structur
ebov
gpcl
illustr
lie
along
crest
line
trough
ebov
gpcl
hydrophob
residu
buri
uncleav
ebov
gp
becom
solvent
expos
trough
ebov
gpcl
systemat
mutat
residu
gpcl
crystal
structur
show
surfaceexpos
cleavag
order
determin
import
bind
viral
infect
defin
receptorbind
site
rb
pseudotyp
vesicular
stomat
viru
vsv
particl
mutant
gp
protein
test
viral
incorpor
gp
rel
incorpor
wildtyp
wt
protein
bind
conform
antibodi
recogn
properli
fold
gp
see
fig
supplement
materi
vsvgp
mutant
met
qualiti
benchmark
evalu
capac
recogn
purifi
solubl
form
human
domain
c
enzymelink
immunosorb
assay
elisa
describ
previous
report
wt
ebov
gpcl
bind
domain
c
effect
concentr
nm
consist
highavid
bind
interact
protein
comparison
find
mutant
demonstr
reduc
infect
also
defect
bind
domain
c
see
fig
supplement
materi
furthermor
singl
point
mutat
caus
drastic
reduct
domain
cbind
locat
around
hydrophob
trough
hydrophil
crest
mutant
allow
us
map
residu
ebov
critic
domain
c
onto
ebov
gpcl
structur
better
defin
rb
see
fig
interestingli
mutat
alanin
two
trough
residu
reduc
viral
infect
dramat
unit
modest
effect
bind
see
fig
dispar
strong
reduct
infect
modest
effect
bind
suggest
residu
may
import
step
viral
entri
bind
prior
membran
fusion
conform
chang
releas
perform
mutagenesi
hydrophob
trough
better
defin
precis
role
sinc
point
mutat
alanin
within
hydrophob
trough
modest
effect
postul
replac
bulkier
methionin
residu
would
complet
occlud
trough
prevent
bind
select
two
trough
residu
inhibit
bind
mutat
alanin
addit
mutagenesi
methionin
fig
b
prevent
misfold
disrupt
gp
structur
engin
compensatori
mutat
interact
residu
glycan
cap
fit
larger
methionin
residu
prevent
steric
clash
engin
follow
mutant
trough
cap
trough
cap
trough
cap
fig
e
simplic
sinc
compensatori
mutat
remov
along
glycan
cap
upon
proteolysi
refer
mutant
mutat
remain
ebov
gpcl
engin
vsvgp
mutant
maintain
high
level
incorpor
compar
incorpor
wt
gp
see
fig
supplement
materi
posit
singl
mutat
well
doubl
mutat
lead
defect
domain
c
bind
pseudoviru
infect
gpcl
bear
fig
c
find
singl
point
mutat
locat
bottom
trough
abrog
domain
c
bind
pseudotyp
viru
infect
fig
posit
suggest
structur
role
mutat
may
destabil
local
trough
structur
prevent
bind
subsequ
infect
togeth
find
provid
evid
support
direct
correl
bind
infect
effect
map
gpcl
trough
critic
compon
site
experi
perform
prior
identif
filoviru
endosom
receptor
demonstr
mutat
map
gpcl
crest
significantli
reduc
viral
infect
investig
whether
observ
reduct
viral
infect
mutat
correl
defect
bind
domain
c
show
individu
mutat
modest
effect
see
fig
supplement
materi
doubl
mutat
dramat
inhibit
domain
c
bind
viral
entri
fig
b
contrast
mutant
show
signific
defect
viral
infect
domain
c
bind
see
fig
test
hypothesi
crest
residu
particip
electrostat
interact
virusreceptor
engag
engin
analyz
vsvgp
lysin
replac
either
basic
acid
residu
doubl
mutant
maintain
basic
charg
remain
fulli
function
contrast
doubl
mutant
revers
charg
display
even
greater
deficit
receptorbind
function
entri
activ
neutral
mutant
fig
b
determin
whether
overal
charg
site
specif
basic
residu
within
site
import
mutat
two
glutam
acid
residu
proxim
posit
alanin
result
quadrupl
mutant
predict
wtlike
electrostat
exhibit
receptorbind
activ
infect
nearli
wt
level
fig
b
import
set
basic
residu
lack
specif
requir
one
individu
suggest
need
maintain
overal
basic
charg
gpcl
crest
fig
high
degre
sequenc
structur
conserv
site
filoviru
glycoprotein
make
attract
target
develop
broadli
neutral
mab
therapeut
potenti
see
fig
supplement
materi
unfortun
mab
ebolavirus
isol
instead
known
neutral
antiebolaviru
mab
target
conform
epitop
base
trimer
recent
howev
sever
mab
isol
human
survivor
marv
infect
found
recogn
hydrophob
gpcl
trough
inhibit
domain
c
bind
signific
one
antimarv
mab
studi
crossreact
purifi
gp
gpcl
ebov
three
mab
crossreact
ebov
gpcl
bind
similar
locat
marv
gp
approach
significantli
differ
angl
third
complementaritydetermin
region
heavi
chain
variabl
region
bind
expect
marv
rb
see
fig
rb
conserv
sequenc
structur
across
known
filovirus
evalu
capac
two
addit
gpclreactiv
antibodi
recogn
neutral
vsv
bear
gpcl
four
ebolavirus
sudan
viru
sudv
bundibugyo
viru
bdbv
forest
viru
tafv
reston
viru
restv
cuevaviru
lloviu
viru
llov
remark
find
effect
neutral
vsv
pseudotyp
gpcl
deriv
known
filovirus
fig
contrast
neutral
vsv
bear
filoviru
gp
weakli
fail
neutral
vsv
bear
gpcl
deriv
speci
marv
specul
steeper
angl
approach
marv
gpcl
compar
may
enhanc
breadth
neutral
improv
access
share
rb
fig
signific
found
fail
bind
vsv
bear
uncleav
ebov
gp
surfac
see
fig
supplement
materi
find
contrast
previou
observ
bind
uncleav
solubl
ebov
gp
ectodomain
see
fig
like
differ
present
ebov
gp
surfac
actual
virion
prevent
bind
effect
neutral
either
wildtyp
ebov
vsv
bear
uncleav
ebov
gp
contrast
neutral
breadth
properti
despit
similar
bind
angl
share
epitop
led
us
explor
panel
gpcl
mutat
identifi
specif
residu
gp
rb
affect
neutral
ebov
gpcl
see
fig
supplement
materi
find
singl
point
mutat
allow
neutral
ebov
gpcl
although
neutral
vsv
bear
wildtyp
ebov
gpcl
neutral
vsvebov
gpcl
fig
posit
ebov
gp
equival
posit
marv
structur
align
ebov
gpcl
marv
marv
crystal
structur
suggest
wildtyp
may
steric
clash
light
chain
replac
valin
smaller
alanin
residu
may
improv
neutral
reliev
steric
clash
fig
furthermor
previou
studi
shown
unlik
fail
block
domain
c
bind
ebov
gpcl
therefor
perform
domain
c
competitivebind
assay
determin
whether
neutral
ebov
inhibit
bind
curious
even
though
abl
neutral
vsv
bear
ebov
remain
unabl
prevent
bind
domain
c
ebov
gpcl
ebov
fig
howev
block
bind
ebov
gpcl
therefor
data
suggest
mab
may
neutral
distinct
mechan
effect
block
bind
filovirus
wherea
block
ebov
bind
specul
neutral
ebov
entri
inhibit
viral
membran
fusion
downstream
viru
receptor
recognit
order
gaug
neutral
potenti
rel
mab
demonstr
protect
efficaci
vivo
perform
compar
analysi
combin
mab
ebovspecif
zmapp
cocktail
well
known
neutral
mab
human
survivor
analysi
demonstr
neutral
pseudovirus
lower
concentr
antibodi
requir
zmapp
cocktail
fig
thu
mab
target
highli
conserv
rb
repres
novel
avenu
broad
potent
neutral
filovirus
deliv
endosom
compart
gpcl
gener
entri
studi
present
crystal
structur
thermolysincleav
ebov
gp
gpcl
prime
interact
filoviru
receptor
thermolysin
previous
demonstr
mimic
host
catb
catl
proteolyt
process
ebov
gp
occur
endosom
requir
receptor
bind
membran
fusion
highresolut
structur
ebov
gpcl
defin
intermolecular
disulfid
bridg
region
previous
unresolv
ebov
gp
disulfid
bridg
like
contribut
inher
stabil
ebolaviru
gp
despit
proteolyt
process
stabil
reflect
high
degre
structur
conserv
uncleav
ebov
gp
gpcl
align
structur
rmsd
crystal
structur
ebov
gpcl
present
also
illustr
proteolyt
prime
remov
glycan
cap
ebov
expos
bind
site
filoviru
receptor
gpcl
crystal
structur
suggest
glycan
cap
may
act
final
layer
defens
shield
critic
conserv
domain
c
bind
site
host
immun
surveil
prior
cellular
entri
show
rb
crestandtrough
morpholog
exist
apex
gpcl
trimer
crest
line
hydrophil
basic
residu
trough
recess
entir
hydrophob
mutagen
analysi
ebov
gpcl
demonstr
crest
involv
nonspecif
electrostat
interact
requir
overal
basic
charg
facilit
bind
domain
c
mutat
ebov
gp
revers
electrostat
charg
gpcl
crest
consist
abrog
receptor
bind
reduc
infect
contrast
gpcl
trough
involv
specif
hydrophob
interact
domain
c
structurebas
mutant
mutat
design
obstruct
structur
trough
diminish
affin
gp
domain
c
sever
restrict
infect
vsv
pseudotyp
bear
mutat
base
crystal
structur
result
mutagenesi
report
propos
receptor
bind
gp
twostag
process
first
gpcl
recruit
domain
c
receptor
nonspecif
electrostat
interact
basic
crest
region
gpcl
without
interact
detect
gpreceptor
bind
next
specif
hydrophob
interact
initi
rb
trough
domain
c
specif
interact
like
explain
differenti
effect
individu
mutat
trough
fig
wherea
effect
mutat
crest
determin
charg
specif
amino
acid
posit
also
analyz
two
mutant
mutat
hydrophob
trough
describ
previous
unabl
support
infect
two
mutant
outlier
analysi
infect
reduc
three
infecti
unit
rel
wt
ebov
gp
despit
modest
defect
bind
domain
c
postul
mutant
defect
step
downstream
bind
provid
use
tool
deciph
precis
bind
facilit
fusion
trigger
membran
fusion
recent
work
identifi
multipl
neutral
mab
patient
surviv
marv
infect
mab
studi
found
bind
apex
marv
site
confirm
filoviru
receptorbind
site
sinc
ebolaviru
marburgviru
cuevaviru
gp
protein
use
protein
receptor
unexpect
structur
rb
would
highli
conserv
across
filovirus
thu
hypothes
mab
identifi
flyak
et
al
shown
target
rb
trough
marv
broadli
neutral
howev
unlik
gp
protein
marburgvirus
ebolavirus
cuevaviru
maintain
glycan
cap
structur
effect
shield
rb
immun
surveil
therefor
proteolyt
prime
filoviru
gp
surfac
vsv
particl
vsvebov
gpcl
abl
analyz
neutral
potenti
mab
target
otherwiseocclud
filoviru
rb
analysi
gpclbear
vsv
would
tell
us
worthwhil
target
antibodi
endosom
futur
therapeut
panel
neutral
mab
marv
survivor
describ
flyak
et
al
one
demonstr
signific
crossreact
uncleav
ebov
gp
three
mab
react
ebov
gpcl
focus
analysi
ebov
gpreactiv
ebov
gpclreactiv
approach
gp
differ
angl
show
effect
neutral
vsv
pseudovirion
bear
gpcl
ebov
sudv
bdbv
tafv
restv
llov
neutral
ebov
bdbv
tafv
llov
vsvgpcl
virion
weakli
restv
sudv
gpcl
infect
never
reduc
see
fig
supplement
materi
contrast
neutral
marv
gpcl
neutral
ebov
gpclbear
vsv
even
though
abl
bind
crystal
structur
marv
gpcl
ebov
gpcl
bound
suggest
bind
site
virus
howev
resolut
ebov
complex
low
identifi
subtl
differ
impos
sequenc
deviat
marv
gp
might
explain
fail
neutral
ebov
gpcl
henc
use
panel
vsvebov
gp
rb
mutant
understand
sequenc
variat
could
prevent
neutral
ebov
gpcl
surprisingli
introduct
singl
point
mutat
within
ebov
rb
allow
neutral
vsvebov
signific
bdbv
tafv
restv
gp
also
encod
valin
posit
sudv
llov
gp
encod
isoleucin
leucin
respect
larger
val
ile
leu
aliphat
residu
encod
ebolavirus
cuevaviru
may
prevent
neutral
gpclbear
particl
fig
see
also
fig
supplement
materi
note
unlik
exhibit
improv
neutral
vsvebov
see
fig
supplement
materi
abl
overcom
diverg
amino
acid
posit
broadli
neutral
filoviru
gpcl
subject
continu
structur
biochem
studi
remark
enhanc
neutral
ebov
accompani
commensur
increas
capac
block
bind
gp
fig
appar
uncoupl
neutral
receptor
blockag
rais
possibl
may
act
alloster
inhibitor
prevent
membran
fusion
bind
subunit
trimer
occupi
domain
c
endosom
may
inhibit
event
occur
receptor
bind
order
trigger
gpmediat
membran
fusion
mutat
like
elimin
infect
without
affect
receptor
bind
may
target
postreceptorbind
step
recent
event
includ
unpreced
ebov
epidem
west
africa
coincid
human
case
marv
emerg
central
africa
emerg
bdbv
reemerg
sudv
decad
highlight
urgent
need
broadspectrum
antifiloviru
therapeut
demonstr
highli
conserv
bind
site
essenti
intracellular
receptor
provid
attract
underexplor
target
broadli
protect
antibodi
smallmolecul
therapeut
howev
one
crucial
challeng
develop
antibodi
therapeut
evolv
featur
filoviru
entri
unavail
site
extracellular
antibodi
success
antivir
strategi
therefor
requir
novel
protein
engin
approach
deliv
gpclspecif
mab
late
endosom
andor
lysosom
site
unmask
host
proteas
ebola
viru
gp
lack
mucin
domain
residu
produc
stabl
express
drosophila
melanogast
cell
briefli
effecten
qiagen
use
transfect
cell
modifi
pmtpuro
vector
plasmid
contain
gp
gene
interest
follow
stabl
select
transfect
cell
puromycin
cell
cultur
complet
schneider
medium
select
adapt
insect
xpress
medium
lonza
largescal
express
erlenmey
flask
secret
gp
ectodomain
express
induc
mm
supernat
harvest
day
ebola
viru
gp
engin
doubl
streptag
c
terminu
facilit
purif
use
streptactin
resin
qiagen
purifi
superdex
size
exclus
chromatographi
sec
mm
trisbuff
salin
trishcl
ph
mm
nacl
tb
ebov
gpcl
produc
incub
mg
gp
mg
thermolysin
overnight
room
temperatur
tb
contain
mm
purifi
use
superdex
sec
trimer
ebov
gpcl
complex
fab
fragment
prior
crystal
previous
describ
purifi
ebov
fab
complex
concentr
mgml
tb
crystal
drop
consist
ratio
proteinwel
solut
well
solut
consist
polyethylen
glycol
monomethyl
ether
peg
mme
ethylen
glycol
mm
sodium
acet
ph
mm
calcium
chlorid
crystal
grew
cours
month
flash
frozen
directli
crystal
drop
liquid
nitrogen
data
collect
data
collect
remot
argonn
nation
laboratori
advanc
photon
sourc
ap
gmca
beamlin
structur
determin
use
molecular
replac
phaser
within
suit
use
modifi
ebov
complex
model
pdb
code
residu
correspond
glycan
cap
remov
refin
ebov
gpcl
crystal
structur
done
iter
cycl
model
build
use
coot
follow
refin
phenix
translationlibrationscrew
tl
motion
appli
refin
tl
motion
determin
tlsmd
server
use
determin
tl
structur
partit
five
percent
data
set
asid
prior
refin
rfree
calcul
data
set
statist
stereochemistri
crystal
structur
check
use
molprob
server
rank
least
percentil
see
fig
supplement
materi
structur
figur
render
use
pymol
pymol
molecular
graphic
system
version
llc
african
grivet
monkey
kidney
vero
cell
maintain
highglucos
dulbecco
modifi
eagl
medium
dmem
invitrogen
corp
carlsbad
ca
supplement
fetal
calf
serum
replicationincompet
vesicular
stomat
viru
vsv
serotyp
indiana
pseudotyp
virus
gener
previous
describ
wild
type
vsvwt
gp
encod
enhanc
green
fluoresc
protein
egfp
place
vsvg
gene
allow
score
infect
bear
ebov
gene
mayinga
isol
genbank
access
number
lack
mucinlik
domain
residu
point
mutant
multipl
mutant
gener
subclon
gp
fragment
contain
mutat
replac
ebov
cleav
vsvgpcl
particl
gener
incub
vsvgp
pseudotyp
thermolysin
h
reaction
stop
ad
phosphoramidon
mm
incub
ice
min
normal
gpcl
amount
use
bind
experi
done
elisa
illustr
fig
supplement
materi
briefli
highbind
elisa
plate
corn
coat
serial
dilut
gpcl
phosphatebuff
salin
pb
allow
bind
h
plate
block
pb
contain
bovin
serum
albumin
pbsa
follow
incub
antigp
monoclon
antibodi
pb
horseradishconjug
antihuman
secondari
antibodi
santa
cruz
biotechnolog
detect
ultratmb
substrat
thermo
scientif
absorb
read
subject
nonlinear
regress
analysi
graphpad
prism
softwar
gener
bind
curv
calcul
valu
addit
virion
normal
gp
incorpor
compar
amount
gp
amount
vsv
matrix
protein
equal
amount
purifi
virion
resolv
sdspage
blot
vsv
matrix
protein
use
mous
antivsv
antibodi
quantif
done
use
licor
ir
dyeconjug
antimous
alexa
fluor
secondari
antibodi
invitrogen
odyssey
imag
station
imag
studio
softwar
licor
bioscienc
result
normal
wt
control
viru
particl
less
incorpor
mutant
gp
compar
incorpor
wt
gp
highli
sensit
proteolysi
exclud
analysi
bind
gp
domain
c
perform
previous
describ
briefli
highbind
elisa
plate
corn
coat
antigp
monoclon
antibodi
pb
follow
block
step
either
uncleav
vitrocleav
gpcl
pseudotyp
captur
plate
unbound
gp
wash
serial
dilut
flagtag
purifi
solubl
human
domain
c
ad
bound
domain
c
detect
horseradishconjug
antiflag
antibodi
sigmaaldrich
use
ultratmb
substrat
thermo
scientif
calcul
bind
curv
gener
nonlinear
regress
analysi
use
graphpad
prism
softwar
bind
elisa
done
duplic
least
two
independ
experi
incub
step
done
h
overnight
serial
dilut
mab
noantibodi
control
mix
either
cleav
uncleav
vsvgp
particl
allow
bind
h
room
temperatur
monolay
vero
cell
inocul
antibodyviru
mixtur
duplic
incub
infect
score
h
postinfect
enumer
egfpposit
cell
fluoresc
microscop
zmapp
cocktail
mab
well
mab
prepar
previous
describ
gener
provid
mapp
biopharmaceut
mab
prepar
previous
describ
coordin
structur
factor
deposit
protein
data
bank
access
number
